P2RX4 antibody Polyclonal Antibodies Primary antibodies
- Known as:
- P2RX4 (anti-) Polyclonal Antibodies Primary antibodies
- Catalog number:
- orb100036
- Product Quantity:
- 100
- Category:
- -
- Supplier:
- Biorb
- Gene target:
- P2RX4 antibody Polyclonal Antibodies Primary antibodies
Related genes to: P2RX4 antibody Polyclonal Antibodies Primary antibodies
- Gene:
- P2RX4 NIH gene
- Name:
- purinergic receptor P2X 4
- Previous symbol:
- -
- Synonyms:
- P2X4
- Chromosome:
- 12q24.31
- Locus Type:
- gene with protein product
- Date approved:
- 1997-10-09
- Date modifiied:
- 2016-10-05
Related products to: P2RX4 antibody Polyclonal Antibodies Primary antibodies
Related articles to: P2RX4 antibody Polyclonal Antibodies Primary antibodies
- P2 purinergic receptors are activated by extracellular adenosine triphosphate and other nucleotides released during inflammatory processes, cellular stress responses, and amplification by NETosis, thereby serving as pivotal mediators of both innate and adaptive immunity. In patients with active systemic lupus erythematosus (SLE), emerging evidence highlights the critical roles of distinct P2 receptors: P2RX4 and P2RY11 in initiating the immune response; P2RY2 in orchestrating immune cell recruitment; P2RX7 in promoting pro-inflammatory states coupled with impaired regulatory mechanisms; and P2RY12 as a driver of type I interferon signaling. Therapeutic targeting of these receptors through selective antagonists has demonstrated efficacy in preclinical lupus-prone models to restore regulatory functions (P2RX7), to control inflammation (P2RX7), type I interferon pathway (P2RY12), autoantibody production (P2RX4 and P2RX7), and glomerulonephritis (P2RX4, P2RX7, P2RY2, and P2RY12). In SLE, selective P2 antagonists are under investigation with major challenges regarding cellular specificity, therapeutic efficacy, and side effects. - Source: PubMed
Publication date: 2026/03/12
Renaudineau YvesBrooks Wesley - Early detection of hepatocellular carcinoma (HCC) remains a persistent worldwide challenge. Owing to its minimal invasiveness, liquid biopsy has emerged as a promising alternative for early screening. As key components of the tumor microenvironment (TME), platelets (PLTs) represent a rich source of biomolecular information that complements the data from conventional plasma and serum samples. Integrative multiomics analysis of such data offers a powerful strategy to deepen our understanding of hepatocarcinogenesis and accelerate the discovery of robust biomarker panels. Here, we described an integrative and ultrafast multiomics sample preparation (IAU-MOSP) strategy for the high-purity platelets. The optimized IAU-MOSP method shortened the multiomics workflow from over 24 to 6 h while yielding comparable biomolecule identifications to those of conventional methods. Then, the workflow was applied in an HCC cohort ( = 68) study. We quantified 6660 biomolecules with high reproducibility (median CVs: 0.31-0.39). The data exhibited strong cross-omics correlations, particularly between proteins and lipids ( = 0.75) as well as protein and metabolite ( = 0.68) groups. Differential analysis revealed 10 biomolecules significantly dysregulated in HCC platelets (TEK, citric acid, glycerol-3-phosphate (G3P), P2RX4, malic acid, ATP, PRG3, ITGAM, CXCR2, ITGB2) that participate in key pathways driving proliferation and metastasis. Accompanied by machine learning, the 10 biomolecules were ultimately identified as a potential biomarker panel for early diagnosis of HCC. It shows superior diagnostic efficacy (accuracy = 0.81, sensitivity = 0.74) over α-fetoprotein (AFP) (accuracy = 0.75, sensitivity = 0.45) for early HCC detection. - Source: PubMed
Publication date: 2026/03/10
Shen FenglinLiu YangRuan XuelianYan GuoquanZhang LeiFang JingLu HaojieHu ZuojianZhou Xinwen - Although FDA-approved medications for alcohol use disorder are available, their efficacy varies across patients, highlighting the need for novel therapeutics that address inter-individual differences in disease etiology and treatment response. Genetic models, particularly heterogeneous stock (HS) rats, recapitulate human-like genetic diversity and behavioral heterogeneity, enabling the dissection of individual differences in vulnerability to AUD and pharmacotherapeutic sensitivity. P2X4 receptors, which are encoded by the gene P2rx4, are ATP-gated ion channels are inhibited by ethanol and abundantly expressed in neurons found in reward and stress circuits. P2X4 receptors have emerged as key modulators of ethanol sensitivity and consumption in preclinical models. Here, we genetically predicted P2rx4 expression in whole brain in 131 male and female HS rats exposed to chronic intermittent ethanol vapor and phenotyped for self-administration during acute abstinence. Rats were dichotomized into genetically predicted high and low expression groups. We found that higher genetically predicted P2rx4 expression was associated with increased post-vapor intake and escalation. In 32 CIE-escalated rats, ivermectin, a positive allosteric modulator of P2X4 receptors, dose-dependently reduced drinking. We stratified rats into three groups: non-responders, mild responders, and high responders. Electrophysiological recordings from CeA slices revealed that ivermectin differentially enhanced GABAergic IPSCs: high-responders exhibited sustained increases in IPSC frequency and selective amplitude reductions, while the two other groups showed transient frequency increases. All groups displayed prolonged rise times, however non-responders showed extended decay times. These findings suggest that P2rx4 upregulation serves as a vulnerability marker for dependence-like behaviors, with ivermectin attenuating withdrawal-driven alcohol consumption by enhancing CeA GABAergic inhibition. - Source: PubMed
Publication date: 2026/02/12
Campo PaolaQiao RanDoyle Michelle RMunro DanielJohnson Benjamin BPalmer Abraham AKallupi Marsidade Guglielmo Giordano - Although FDA-approved medications for alcohol use disorder (AUD) are available, their efficacy varies across patients, highlighting the need for novel therapeutics that address interindividual differences in disease etiology and treatment response. Genetic models, particularly heterogeneous stock (HS) rats, recapitulate human-like genetic diversity and behavioral heterogeneity, enabling the dissection of individual differences in vulnerability to AUD and pharmacotherapeutic sensitivity. P2X4 receptors, which are encoded by the gene , are ATP-gated ion channels inhibited by ethanol and abundantly expressed in neurons found in reward and stress circuits. P2X4 receptors have emerged as key modulators of ethanol sensitivity and consumption in preclinical models. Here, we genetically predicted expression in whole brain in a cohort of 130 HS rats exposed to chronic intermittent ethanol (CIE) vapor and phenotyped for self-administration during acute abstinence. Rats were dichotomized into high- and low-predicted expression groups. Higher predicted expression was associated with increased post-vapor intake and escalation. In 32 CIE-escalated rats, ivermectin, a positive allosteric modulator of P2X4 receptors, dose-dependently reduced drinking. We stratified rats into three groups: non-responders, mild responders, and high responders. Electrophysiological recordings from CeA slices revealed that ivermectin differentially enhanced GABAergic IPSCs: high-responders exhibited sustained increases in IPSC frequency and selective amplitude reductions, while the two other groups showed transient frequency increases. All groups displayed prolonged rise times, however non-responders showed extended decay times. These findings suggest that upregulation serves as a vulnerability marker for dependence-like behaviors, with ivermectin attenuating withdrawal-driven alcohol consumption by enhancing CeA GABAergic inhibition. - Source: PubMed
Publication date: 2025/10/15
Campo PaolaQiao RanDoyle Michelle RMunro DanielJohnson Benjamin JPalmer Abraham AKallupi Marsidade Guglielmo Giordano - Hepatocellular carcinoma (HCC) is frequently identified at advanced stages. This constrains therapeutic options and results in poor prognosis. P2RX4 is an ATP-gated ion channel that modulates calcium influx. It participates in cellular proliferation, inflammatory processes, and immunological reactions. Nonetheless, its role in HCC remains poorly comprehended. This study explored the expression, function, and immunological effects of P2RX4 in HCC. - Source: PubMed
Publication date: 2025/10/09
Wang JianrongGu YanmeiNiu ZeTang FutianLi Yumin